Table 2. Baseline characteristics of IgM/IgG positive/negative patients with COVID-2019.
| Variables | IgM (n = 163) | p | IgG (n = 163) | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | p | ||
| No. | 130 | 33 | 127 | 36 | ||
| Age, year | 53.86 ± 14.98 | 57.52 ± 15.31 | 0.2147a | 54.02 ± 14.97 | 56.67 ± 15.49 | 0.3533a |
| Gender | ||||||
| Male, n (%) | 75 (57.69%) | 13 (39.39%) | 0.0596b | 75 (59.06%) | 13 (36.11%) | 0.0148b |
| Female, n (%) | 55 (42.31%) | 20 (60.61%) | 52 (40.94%) | 23 (63.89%) | ||
| Comorbidities | ||||||
| Diabetes, n (%) | 22 (16.92%) | 5 (15.15%) | 0.8069b | 22 (17.32%) | 5 (13.89%) | 0.6247b |
| Hypertension, n (%) | 33 (25.38%) | 15 (45.45%) | 0.0239b | 33 (25.98%) | 14 (38.89%) | 0.1314b |
| Cardia-cerebrovascular disease, n (%) | 20 (15.38%) | 11 (33.33%) | 0.0190b | 21 (16.54%) | 10 (27.78%) | 0.1292b |
| Respiratory diseases, n (%) | 5 (3.85%) | 3 (9.09%) | 0.2130b | 4 (3.15%) | 4 (11.11%) | 0.0724b |
| Tumor, n (%) | 3 (2.31%) | 2 (6.06%) | 0.2665b | 3 (2.36%) | 2 (5.56%) | 0.3051b |
| Clinical classification | ||||||
| Mild, n (%) | 2 (1.54%) | 0 (0) | N/A | 2 (1.57%) | 0 (0) | N/A |
| General, n (%) | 86 (66.15%) | 18 (54.55%) | 0.2153b | 82 (64.57%) | 22 (61.11%) | 0.7033b |
| Severe, n (%) | 23 (17.69%) | 2 (6.06%) | 0.1121b | 23 (18.11%) | 2 (5.56%) | 0.0650b |
| Critical, n (%) | 19 (14.62%) | 13 (39.39%) | 0.0014b | 20 (15.75%) | 12 (33.33%) | 0.0190b |
| Positive conversion time for SARS-CoV-2 RNA | 7.50 (4.00–13.00) | 5.00 (3.00–7.50) | 0.0228c | 8.00 (4.00–13.00) | 5.00 (3.00–7.00) | 0.0022c |
| Clinical laboratory test | ||||||
| WBC, 10^9/L | 5.59 (4.46–7.35) | 4.86 (3.44–8.58) | 0.4902c | 5.63 (4.53–7.42) | 4.82 (3.40–8.32) | 0.3250 c |
| Neutrophil, 10^9/L | 3.47 (2.40–5.17) | 3.47 (1.85–7.41) | 0.8751c | 3.56 (2.44–5.24) | 3.17 (1.93–7.08) | 0.5982c |
| Lymphocyte, 10^9/L | 1.30 ± 0.61 | 0.90 ± 0.43 | 0.0005a | 1.29 ± 0.61 | 0.97 ± 0.49 | 0.0046a |
| Monocyte, 10^9/L | 0.45 (0.33–0.64) | 0.42 (0.31–0.56) | 0.3646c | 0.44 (0.34–0.64) | 0.42 (0.31–0.56) | 0.4724c |
| RDW, (%) | 13.20 (12.68–13.70) | 13.10 (12.55–13.95) | 0.9975c | 13.20 (12.70–13.70) | 13.05 (12.43–13.90) | 0.7160c |
| Glucose, mmol/L | 5.48 (4.86–6.85) | 5.98 (5.12–6.99) | 0.2702c | 5.49 (4.86–7.02) | 5.82 (5.09–6.77) | 0.3930c |
| ALT, U/L | 27.00 (18.75–50.25) | 24.00 (14.50–41.50) | 0.2106c | 28.00 (20.00–50.25) | 20.50 (14.00–39.50) | 0.0274c |
| AST, U/L | 25.50 (19.00–30.00) | 26.00 (19.50–51.00) | 0.5849c | 26.00 (19.00–40.00) | 25.50 (16.50–47.75) | 0.5491c |
| BUN, mmol/L | 4.56 (3.71–5.66) | 5.21 (3.49–8.36) | 0.1119c | 4.55 (3.72–5.65) | 5.15 (3.53–7.91) | 0.1291c |
| CRP, mg/L | 8.45 (2.08–46.15) | 15.23 (3.03–43.90) | 0.5316c | 8.90 (2.00–48.70) | 10.90 (2.95–44.15) | 0.6416c |
Data was displayed as mean ± SD, median (IQR, interquartile range), or n (%).
atwo-tailed Student’s t test
bχ² test
cnon-parametric test (Mann–Whitney U test)
Positive conversion time for SARS-CoV-2 RNA defined as the first positive time point of RNA tests.
p < 0.05 was considered statistically significant (in bold).
Abbreviation: WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; RDW, red blood cell distribution width; N/A, not applicable.